Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

CRESIB coordinates an international consortium to fight malaria caused by Plasmodium vivax

18.07.2007
The CRESIB has today presented the research programme on malaria by Plasmodium vivax, a parasite causing over 70 million yearly cases of malaria in the world. This new programme will be developed in coordination with the leading international centres and researchers on P.vivax.

The aim of this study is to contribute to a better understanding of malaria by P. vivax and to support and accelerate the development of new control tools, with a special focus in vaccines. This fact will promote the creation and development of a research line on P. vivax in CRESIB under the direction of Dr. Hernando A. del Portillo, one of the few specialists in molecular biology and vaccine development against this parasite. The number of CRESIB labs will be increased, with an enlargement and restoration of current facilities to meet the needs of the centre.

Malaria is an infectious disease which can be caused by four species of the Plasmodium parasite: P. falciparum, P. vivax, P. malariae and P. ovale. P. falciparum and P. vivax are the most prevalent, the first being more virulent and responsible of most of the severe morbidity and mortality. Nevertheless, during the last years, there has been a growing interest in malaria by P. vivax, which, as well as causing millions of malaria cases every year, it also generates a high social and economic cost for endemic countries. It is estimated that about 2,600 million people live in risk zones for P. vivax: central and south-America, Asia, Middle East and occidental Pacific. Clinical and pathogen presentation of P. vivax is not well understood. Despite the traditional belief that clinical malaria caused by this species of the parasite is mild, there are evidences suggesting that it can cause severe clinical patterns and even death of patients.

The paradox is that even though malaria by P. vivax has large global disease burden, this is a poorly studied disease, which has been long forgotten. Consequently, this new research programme has a large importance, and an estimated initial duration of 4 years.

This is the reason why CRESIB, through DR. Hernando A. del Portillo, specialist in molecular biology and vaccine development against Plasmodium vivax, gives plenty of importance to the development of new control tools for this type of malaria.

In the field of malaria by P. vivax, there has been until now a lack of initiatives to promote the global effort in the research on this disease. With the experience of the CRESIB group in malaria and of the Clínic Foundation for Biomedical Research (FCRB, Fundació Clínic per a la Recerca Biomèdica) in the management and coordination of projects of international research, an international consortium of research in P. vivax will be created and promoted. This consortium will be constituted by leading malaria research centres, and will be coordinated from Barcelona.

Research centres collaborating in this project, mostly placed in malaria endemic areas by Plasmodium vivax, are: Papua New Guinea Institute of Medical Research, located in Papua New Guinea; the International Centre for Genetic Engineering and Biotechnology, located in New Delhi (India), the Tropical Medicine Foundation of Amazonas, in Manaus (Brazil) and the International Vaccine Centre, located in Cali (Colombia).

About CRESIB:
Research on poverty-related diseases is one of our main tools to try to break the vicious circle between disease and poverty and to have an impact on the development of low-income countries. It is in this sense that the CRESIB has been created in Catalonia, an institute born from the scientific support of the International Health Centre of Hospital Clínic and founded by the Catalan Government through the Department of Health and the Department of Innovation, Universities and Enterprises; the Universitat de Barcelona(UB); the Hospital Clínic de Barcelona; and the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) with the objective to conduct excellence research in international health and to contribute to the global effort in the fight against poverty-related diseases.

CRESIB has a scientific programme including research on diseases causing an important part of the morbidity and mortality in low-income countries, specially malaria, acute respiratory infections, diarrhoeas, tuberculosis and AIDS. Furthermore, CRESIB sets its sights on promoting research related to other aspects of international health, such as emergent, reemergent and immunopreventable diseases, health, immigration and climate and health. Research conducted by CRESIB researchers is currently developed in the facilities located in the Campus of the Faculty of Medicine of the Universitat de Barcelona-Hospital Clínic.

Department of Communication and External Relations of the IDIBAPS - Hospital Clínic of Barcelona

For further information, please contact us at +34 93 227 57 00
Marc de Semir/Gemma Moya

Marc de Semir | EurekAlert!
Further information:
http://www.cresib.cat
http://www.ub.es

More articles from Health and Medicine:

nachricht The end of pneumonia? New vaccine offers hope
23.10.2017 | University at Buffalo

nachricht Scientists track ovarian cancers to site of origin: Fallopian tubes
23.10.2017 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>